Fig. 1 A



160
140
120
100
80
60
40
20
0
relative resistance [%]
0
5
10
15
20
25
30
Time[h]
Kontrolle
5,0*10^8
7,42*10^8
1,00*10^9
1,50*10^9
2,00*10^9
1,00*10^10

Fig. 1 B



120
100
80
60
40
20
0
Resistance / (%)
0
5
10
15
20
25
time / (h)
Control
1,5*10^10
2,00*10^10
1,00*10^11
2,00*10^11
1,00*10^12
2,00*10^12

Fig. 2



3,60E+07
3,10E+07
2,60E+07
2,10E+07
1,60E+07
1,10E+07
6,00E+06
1,00E+06
detected VLPs
4,60E+07
6,00E+07
1,80E+08
1,00E+09
2,75E+09
3,00E+09
added VLPs
apical
basolateral

Fig. 3



5 µg salt precipitated VLPs
50 µg salt precipitated VLPs
5 µg chromatographic purified VLPs
DNA control
VLPs control
ROI 4
ROI 1
ROI 3
ROI 2
ROI 4
ROI 4
ROI 8
ROI 1
ROI 5
ROI 1
ROI 5
ROI 2
ROI 6
ROI 4
ROI 8

Fig. 4



BLI signal in head after intravenous VLPs applications in comparison to the VLP Control group
Gesamtfluss [p/s]/10⁶
4
3
2
1
0
-1
-2
2
4
8
15
21
24
Day after application
5µg salt precipitated VLPs - VLP Control
50µg salt precipitated VLPs - VLP Control
5µg chromatographic purifiedV ,Ps - VLP Control
DNA Control - VLP Control

Fig. 5 A



Transduction I
RLU
1,81E+06
1,61E+06
1,41E+06
1,21E+06
1,01E+06
8,10E+05
6,10E+05
4,10E+05
2,10E+05
1,00E+04
25µg VLP packed
50µg VLP packed
50µg VLP packed
50µg VLP mixed
DNA Control

Fig. 5 B



Transduction II
RLU
5,50E+06
5,00E+06
4,50E+06
4,00E+06
3,50E+06
3,00E+06
2,50E+06
2,00E+06
1,50E+06
1,00E+06
5,00E+05
25µg VLP packed
50µg VLP packed
50µg VLP mixed
50µg VLP packed
50µg VLP mixed
DNA Control

Fig. 6




Fig. 7





Fig. 8


DAPI-Cell nucleus
VP1 protein
DAPI
FITC
TRITC
Custom
Cell biomarker Olig2
Merge